Oliver Sartor
Oliver Sartor is an American oncologist and research scientist. He is currently the director of the Transformational Prostate Cancer Research Center at East Jefferson General Hospital Cancer Center in Metairie, Louisiana and adjunct faculty at Tulane University School of Medicine. He was previously the chair of the genitourinary cancer disease group and director of radiopharmaceutical clinical trials at Mayo Clinic Rochester, and before that he was the assistant dean for oncology and the C.E. and Bernadine Laborde Professor of Cancer Research, Medicine and Urology Departments at the Tulane School of Medicine in New Orleans, Louisiana. His research has mainly focused on translational science and clinical research trials of advanced prostate cancer since 1990 and he is recognized as an expert in that field through his contributions to the practice and the publishing of over 500 peer-reviewed articles and numerous book chapters and reviews. Sartor also serves as the editor-in-chief of the bimonthly journal ''Clinical Genitourinary Cancer'' that mainly focuses on research in genitourinary oncology. Provided by Wikipedia
Showing 1 - 4 results of 4 for search 'Oliver Sartor', query time: 0.01s
Refine Results
-
1
Hematologic dysfunction and myeloid neoplasm risk in patients treated with lutetium-177 prostate specific antigen membrane therapy by Yael Kusne, Osama M. Mosalem, Jaxon Quillen, Skye Buckner-Petty, Miguel Muniz, Oliver Sartor, Geoffrey B. Johnson, Daniel S. Childs, Mrinal M. Patnaik
Published 2025-04-01Get full text
Article -
2
Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA by Neeraj Agarwal, Oliver Sartor, Brian Lewis, Hani Babiker, Elisa Ledet, Lesli Kiedrowski, Pedro Barata, Roberto Nussenzveig, Benjamin Gerendash, Ellen Jaeger, Whitley Hatton, Jodi Layton, Alan Bryce, Cy Stein, Philip Saylor
Published 2020-10-01Get full text
Article -
3
Initial clinical experience with [177Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer: dosimetry, safety, and efficacy from the lead-in cohort o... by Aaron R. Hansen, Stephan Probst, Jean-Mathieu Beauregard, Benjamin L. Viglianti, Jeff M. Michalski, Scott T. Tagawa, Oliver Sartor, Ronald F. Tutrone, Orhan K. Oz, Kevin D. Courtney, Ebrahim S. Delpassand, Luke T. Nordquist, Medhat M. Osman, Kim N. Chi, Richard Sparks, Noble George, Sara M. Hawley, Wenting Wu, Jessica D. Jensen, Neil E. Fleshner
Published 2025-01-01Get full text
Article -
4
Blood-based tumor mutational burden impacts clinical outcomes of immune checkpoint inhibitor treated breast and prostate cancers by Reagan M. Barnett, Albert Jang, Sree Lanka, PIngfu Fu, Leslie A. Bucheit, Hani Babiker, Alan Bryce, Haley M. Meyer, Yujin Choi, Casey Moore, Rohan Garje, Xin Gao, Dae Won Kim, Richard Y. Chang, Pat Gulhati, Ryne Ramaker, Rani Bansal, Tian Zhang, A. Oliver Sartor, Andrew J. Armstrong, Mehmet A. Bilen, Pedro Barata
Published 2024-12-01Get full text
Article